Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus dostarlimab as induction and maintenance therapy in HPV-negative head and neck squamous cell carcinoma
2019-004875-38Phase 2Active
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Gruppo Oncologico Nord Ovest. Started Jul 2021; status: active.
02
Drugs
niraparibdostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2019-004875-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004875-38.